InvestingPro’s Fair Value spotted 65% gain in Inspire Medical stock

In early June 2026, Inspire Medical Systems' stock was quoted at $41.19. InvestingPro's Fair Value analysis deemed it significantly undervalued, with an intrinsic Fair Value of $62.22, indicating a potential 48% upside. Three months later, the stock had surged by 65%, corroborating the analysis. This healthcare technology firm, specializing in hypoglossal nerve stimulation therapy for sleep apnea, demonstrated solid fundamentals with $915 million in revenue, $67.3 million in EBITDA, and an EPS of $4.50.

Although the stock exhibited volatility over the previous six months, with monthly returns ranging from -26% to +9%, Inspire Medical Systems' market leadership, strong gross profit margin of 84.47%, and robust balance sheet with more cash than debt made the stock a compelling value proposition. Following its identification at $41.19, the stock climbed steadily, reaching $68.12 and then $73 by early September—an impressive 65.38% total return, surpassing the model's estimated 51% upside.

The stock's consistent monthly gains of 7.9%, 12.6%, 25.5%, and 15.9% throughout the summer highlighted the precision of InvestingPro's Fair Value methodology, which presently estimates the intrinsic value at $79.40. Recent positive developments, including Q2 2026 earnings beating expectations and upgrades by analysts, have reinforced the bullish outlook.

Inspire Medical Systems' Q2 financials showed EBITDA of $71.3 million and EPS of $4.66, reflecting operational progress. The company's Inspire V product launch further expands its addressable market in sleep apnea treatment. InvestingPro's Fair Value analysis aggregates multiple valuation methods to estimate intrinsic worth, considering future cash flows and incorporating a margin of safety to identify potentially mispriced stocks.